Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

Cited by (684)

Items 401–500 of 684

1. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
   Tanaka, Hiroaki, Sakagami, Hideki, Kaneko, Naoki, Konagai, Satoshi, Yamamoto, Hiroko, Matsuya, Takahiro, Yuri, Masatoshi, Yamanaka, Yosuke, Mori, Masamichi, Takeuchi, Masahiro et al. · 2019 · Molecular Cancer Therapeutics
2. EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
   Yuanzhuo Gu, Hongchao He, Shilei Qiao, Yifan Shao, Lurong Wang, Zhengkui Zhang, Long Zhang, Fangfang Zhou · 2025 · Advanced Science
3. A new generation of EGFR inhibition
   David Killock · 2015 · Nature Reviews Clinical Oncology
4. Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
   Jin Kyung Rho, In Yong Lee, Yun Jung Choi, Chang‐Min Choi, Jae-Young Hur, Jong Sung Koh, Jaekyoo Lee, Byung‐Chul Suh, Ho‐Juhn Song, Paresh Salgaonkar et al. · 2017 · Cancer Research
5. Detection of epidermal growth factor receptor gene T790M mutation in cytology samples using the cobas ® EGFR mutation test
   Miyako Satouchi, Hiroshi Tanaka, Hiroshige Yoshioka, Tadasuke Shimokawaji, Keiko Mizuno, Koji Takeda, Ichiro Yoshino, Takashi Seto, Takayasu Kurata, Naoki Tashiro et al. · 2017 · Lung Cancer
6. Reducing Artifactual EGFR T790M Mutations in DNA from Formalin-Fixed Paraffin-Embedded Tissue by Use of Thymine-DNA Glycosylase
   Hongdo Do, Ramyar Molania, Paul L. Mitchell, Rita Vaiškunaite, John D. Murdoch, Alexander Dobrovic · 2017 · Clinical Chemistry
7. Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer
   Priyanka Bhateja, Afshin Dowlati, Neelesh Sharma · 2017 · Investigational New Drugs
8. HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
   Sho Watanabe, Yasushi Goto, Hiroyuki Yasuda, Takashi Kohno, Noriko Motoi, Yuichiro Ohe, Hiroyoshi Nishikawa, Susumu S. Kobayashi, Kazuyoshi Kuwano, Yosuke Togashi · 2021 · Thoracic Cancer
9. Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer
   Barbara L. Melosky · 2017 · Frontiers in Oncology
10. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer
    Prabhat Singh Malik, Deepali Jain, Lalit Kumar · 2016 · Oncology
11. Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
    Sijia Ren, Chunguo Wang, Jianfei Shen, Chengchu Zhu · 2020 · Journal of Thoracic Disease
12. Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
    Raffaele Califano, Ourania Romanidou, Giannis Mountzios, Lorenza Maria Landi, Federico Cappuzzo, Fiona Helen Blackhall · 2016 · Drugs
13. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
    Tinghui Wu, Emily Han-Chung Hsiue, Jih‐Hsiang Lee, Chia‐Chi Lin, James Chih‐Hsin Yang · 2016 · Expert Review of Respiratory Medicine
14. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
    Jong‐Mu Sun, Keunchil Park · 2017 · Current Opinion in Oncology
15. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients
    Tiziana Vavalà, Alessandro Follador, Marcello Tiseo, Domenico Galetta, Alessandro Morabito, Massimo Di Maïo, Olga Martelli, Orazio Caffo, Pier Luigi Piovano, Diego Luigi Cortinovis et al. · 2016 · Lung Cancer
16. Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr
    Sang Min Lim, Yujeong Jeong, Sungwoo Hong · 2016 · Future Medicinal Chemistry
17. Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
    Àlvaro Quintanal-Villalonga, Luis G Paz-Ares, Irene Ferrer, Sonia Molina‐Pinelo · 2016 · Disease Markers
18. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer
    Norimitsu Kasahara, Hirotsugu Kenmotsu, Masakuni Serizawa, Rina Umehara, Akira Ono, Yasushi Hisamatsu, Kazushige Wakuda, Shota Omori, Kazuhisa Nakashima, Tetsuhiko Taira et al. · 2017 · Lung Cancer
19. Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients
    Lei‐Yun Wang, Jiajia Cui, Ao-Xiang Guo, Ji‐Ye Yin · 2018 · OncoTargets and Therapy
20. Towards Circulating-Tumor DNA-Based Precision Medicine
    Ai Hironaka‐Mitsuhashi, Anna Sanchez Calle, Takahiro Ochiya, Shin Takayama, Akihiko Suto · 2019 · Journal of Clinical Medicine
21. Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing
    Yue Zhao, Jun Ying He, Jun Cui, Zi-Qi Meng, Yue Li Zou, Xiao Su Guo, Xin Chen, Xueliang Wang, Li-Tian Yan, Wei Han et al. · 2020 · BMC Cancer
22. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model
    Petra Martin, Erin Stewart, Nhu‐An Pham, Céline Mascaux, Devang Panchal, Ming Li, Lucia Kim, Shingo Sakashita, Dennis Y.Q. Wang, Jenna R. Sykes et al. · 2016 · Clinical Lung Cancer
23. EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts
    Elena D. Lavdovskaia, Aglaya G. Iyevleva, Анна Петровна Соколенко, Natalia V. Mitiushkina, Елена Васильевна Преображенская, Vladislav I. Tiurin, Alexandr O. Ivantsov, Бизин Илья Валерьевич, Liliya V. Stelmakh, Fedor Vladimirovich Moiseenko et al. · 2018 · Oncology Research and Treatment
24. Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper
    Nicola Silvestris, Antonella Argentiero, Giordano Domenico Beretta, Paolo Di Bartolo, Monica Montagnani, Romano Danesi, Pietro Ferrari, Stella D’Oronzo, Stefania Gori, Antonio Dello Russo et al. · 2020 · Critical Reviews in Oncology/Hematology
25. Research progress on the multi-omics and survival status of circulating tumor cells
    Qingming Xie, Shilei Liu, Sai Zhang, Liqiu Liao, Zhi Xiao, Shouman Wang, Pengfei Zhang · 2024 · Clinical and Experimental Medicine
26. From Rarity to Reality: Osimertinib’s Promising Horizon in Treating Uncommon EGFR Mutations in Non–Small Cell Lung Cancer
    Akito Fukuda, Yusuke Okuma · 2024 · Clinical Cancer Research
27. Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial
    Oscar G. Arrieta, Graciela Cruz‐Rico, Enrique Soto‐Pérez‐de‐Celis, Laura-Alejandra Ramírez-Tirado, Enrique Caballé‐Perez, Jorge-Negueb Martínez-Hernández, Ivan Martinez-Alvarez, Giovanny Soca‐Chafre, Eleazar Omar Macedo-Pérez, Horacio Astudillo‐de la Vega · 2016 · Targeted Oncology
28. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
    C.I. Edvard Smith · 2016 · Seminars in Cancer Biology
29. Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
    Xiao-Nan Zhang, Lei Huang · 2017 · Oncotarget
30. Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation
    Yu Chen, Juan Deng, Yu Liu, Hao Wang, Sha Zhao, Yayi He, Caicun Zhou · 2021 · Annals of Translational Medicine
31. Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
    Daniela Ferreira, Juliana Miranda, Paula Martins‐Lopes, Filomena Adega, Raquel Chaves · 2021 · International Journal of Molecular Sciences
32. Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer
    Sunil Kumar Surapaneni, Ebony Nottingham, Arindam Mondal, Nilkumar Patel, Peggy Arthur, Aragaw Gebeyehu, Anil Kumar Kalvala, Arun K. Rishi, Mandip S. Singh · 2021 · Anticancer Research
33. Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
    Yuli Wang, Zhitao Guo, Li Yang, Qinghua Zhou · 2016 · Open Medicine
34. Transient appearance of circulating tumor DNA associated with de novo treatment
    Kikuya Kato, Junji Uchida, Yoji Kukita, Toru Kumagai, Kazumi Nishino, Takako Inoue, Madoka Kimura, Fumio Imamura · 2016 · Scientific Reports
35. Live, Learn, Pass It on
    Sydney Morss Dy, Ellen M. Janssen, Andrea A. Ferris, John F. P. Bridges · 2017 · Journal of Patient Experience
36. Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold
    Jinxing Hu, Yufei Han, Jingtao Wang, Yue Liu, Yanfang Zhao, Yajing Liu, Ping Gong · 2018 · Bioorganic & Medicinal Chemistry
37. Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
    Aaron C. Tan, Yi Lin Teh, Gillianne Geet Yi Lai, Daniel Shao-Weng Tan · 2019 · Expert Review of Anticancer Therapy
38. Synthesis of Radiopharmaceuticals via “In-Loop” 11C-Carbonylation as Exemplified by the Radiolabeling of Inhibitors of Bruton's Tyrosine Kinase
    David J. Donnelly, Sean Preshlock, Tanpreet Kaur, Tritin Tran, Thomas C. Wilson, Karim Mhanna, Bradford D. Henderson, Daniel Batalla, Peter J. H. Scott, Xia Shao · 2022 · Frontiers in Nuclear Medicine
39. Outcomes of research biopsies in clinical trials of EGFR mutation-positive non-small cell lung cancer patients pretreated with EGFR-tyrosine kinase inhibitors
    Bin-Chi Liao, Ya-Ying Bai, Jih‐Hsiang Lee, Chia‐Chi Lin, Shu‐Yung Lin, Yee-Fan Lee, Chao‐Chi Ho, Jin‐Yuan Shih, Yeun‐Chung Chang, Chong‐Jen Yu et al. · 2017 · Journal of the Formosan Medical Association
40. Prevalence of Epidermal Growth Factor Receptor Mutations in Patients with Non-Small Cell Lung Cancer in Turkish Population
    Gaye Güler Tezel, Ebru Şener, Çisel Aydın, Sevgen Celik Onder · 2017 · Balkan Medical Journal
41. Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis
    Xiaoli Wu · 2017 · Gene
42. Liquid Biopsy as Surrogate to Tissue in Lung Cancer for Molecular Profiling: A Meta-analysis
    Mona Mlika, Chadli Dziri, Mohamed Majdi Zorgati, Mehdi Ben Khelil, Faouzi El Mezni · 2018 · Current Respiratory Medicine Reviews
43. Advances in drug development for targeted therapies for glioblastoma
    Yan Ge, Yunfu Wang, Jincao Chen, Wenzhong Zheng, Changzhen Liu, Shi Chen, Lianrong Wang, Jie Luo, Zhiqiang Li · 2020 · Medicinal Research Reviews
44. Design, synthesis and SAR study of 2-aminopyrimidines with diverse Michael addition acceptors for chemically tuning the potency against EGFRL858R/T790M
    Jiaan Shao, Shuangrong Liu, Xingyu Liu, Youlu Pan, Wenteng Chen · 2020 · Bioorganic & Medicinal Chemistry
45. Molecular profiling of afatinib-resistant non-small cell lung cancer cells in vivo derived from mice
    Cheng-Ta Chung, Kai‐Chia Yeh, Chia‐Huei Lee, Yunyu Chen, Pai-Jiun Ho, Kai-Yen Chang, Chieh‐Hsin Chen, Yiu‐Kay Lai, Chiung‐Tong Chen · 2020 · Pharmacological Research
46. Resistance to Therapy
    Gabriel A. Rivera, Heather A. Wakelee · 2016 · Cancer treatment and research
47. Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non‐small‐cell lung carcinoma
    Lavinia Tan, Marliese Alexander, Ann Officer, Michael Patrick MacManus, Linda Mileshkin, Ross R. Jennens, Dishan Herath, Richard DE BOER, Stephen B. Fox, David Ball et al. · 2017 · Internal Medicine Journal
48. Diarrhea with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: A meta-analysis of randomized controlled trials
    Jing Li, Jian Hong Gu · 2018 · Critical Reviews in Oncology/Hematology
49. Pharmacological management of relapsed/refractory NSCLC with chemical drugs
    Niki Karachaliou, Aaron E. Sosa, Feliciano Barrón, María González Cao, Mariacarmela Santarpía, Rafael Rosell · 2017 · Expert Opinion on Pharmacotherapy
50. Update in Lung Cancer 2015
    Avrum E. Spira, Balázs Halmos, Charles A. Powell · 2016 · American Journal of Respiratory and Critical Care Medicine
51. Real‐world outcomes of NSCLC patients receiving tissue or circulating tumor DNA‐guided osimertinib treatment
    Po‐Lan Su, Szu‐Chun Yang, Yilin Chen, Yilin Wu, Chia‐Ying Lin, Wei‐Yuan Chang, Yau‐Lin Tseng, Wu‐Wei Lai, Chung‐Liang Ho, Chien‐Chung Lin et al. · 2019 · Cancer Medicine
52. Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients
    Maria Lucia Reale, Rita Chiari, Marcello Tiseo, Fabiana Vitiello, Fausto Barbieri, Diego Luigi Cortinovis, Giovanni Luca Ceresoli, Giovanna Finocchiaro, Gianpiero Diego Romano, Pier Luigi Piovano et al. · 2019 · Lung Cancer
53. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
    Rashmi R. Shah · 2016 · Drug Safety
54. Treatment in EGFR-mutated Non-small Cell Lung Cancer: How to Block the Receptor and overcome Resistance Mechanisms
    Claudia Proto, Giuseppe Lo Russo, Giulia Corrao, Monica Ganzinelli, Francesco Facchinetti, Roberta Minari, Marcello Tiseo, Marina Chiara Garassino · 2017 · Tumori Journal
55. EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non–Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor
    Jonathan Wade Goldman, Chris Karlovich, Lecia Van Dam Sequist, Vlada Melnikova, Aleksandra Franovic, Shirish M. Gadgeel, Karen L. Reckamp, D. Ross Camidge, Maurice Pérol, Sai‐Hong Ignatius Ou et al. · 2018 · JCO Precision Oncology
56. An in Vitro Assay of hERG K+ Channel Potency for a New EGFR Inhibitor FHND004
    Tao Jin, Bingxue Hu, Shanshan Chen, Qiang Wang, Xue Yuan Dong, Yin Zhang, Yongqiang Zhu, Zhao Zhang · 2018 · Frontiers in Pharmacology
57. ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting
    Shirong Zhang, Lucheng Zhu, Xueqin Chen, Xiaochen Zhang, Enguo Chen, Hongming Fang, Yuejuan Feng, Yuping Li, Xi Wang, Zhongyu Jiang et al. · 2018 · Journal of Thoracic Disease
58. FGFR genes mutation is an independent prognostic factor and associated with lymph node metastasis in squamous non-small cell lung cancer
    Jing Jing Li, Shi Yan, Yaqi Pan, Zhen Liu, Ying Liu, Qiuju Deng, Qin Tan, Emma Roisin Woodward, Nan Wu · 2018 · Cancer Biology & Therapy
59. Nazartinib in EGFR Thr790Met-mutant non-small-cell lung cancer
    Jassem, Jacek, Dziadziuszko, Rafał · 2020 · The Lancet Respiratory Medicine
60. Targeting EGFR and ALK in NSCLC: Current Evidence and Future Perspective
    Chiara Bennati, Luca Paglialunga, Biagio Ricciuti, Giulio Metro, Luca Marcomigni, Alessio Gili, Lucio Crinò · 2016 · Lung Cancer Management
61. Synthesis and evaluation of a rociletinib analog as prospective imaging double mutation L858R/T790M in non-small cell lung cancer
    Muammar Fawwaz, Kenji Mishiro, Bambang Purwono, Ryuichi Nishii, Kazuma Ogawa · 2023 · Journal of Pharmacy & Pharmacognosy Research
62. Metformin synergistically enhances the antitumor activity of the third‐generation EGFR‐TKI CO‐1686 in lung cancer cells through suppressing NF‐κB signaling
    Yonghong Pan, Caiyu Lin, Conghua Lu, Li Li, Yubo Wang, Hengyi Chen, Yong He · 2018 · The Clinical Respiratory Journal
63. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors
    Debroop Basu, Riya Pal, Maitrayee Sarkar, Soubhik Barma, Sumit Halder, Harekrishna Roy, Sisir Nandi, Asmita Samadder · 2023 · Current Topics in Medicinal Chemistry
64. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
    Emily H. Castellanos, Leora Horn · 2015 · Current Treatment Options in Oncology
65. Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature
    Sheng Jie Guo, Dawei Chen, Xuesong Huang, Jie Cai, Jean‐Pierre Wery, Qi‐Xiang Li · 2016 · Oncotarget
66. TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Kimihiro Ito, Makoto Nishio, Masanori Kato, Haruyasu Murakami, Yoshimi Aoyagi, Yuichiro Ohe, Takashige Okayama, Akihiro Hashimoto, Hirokazu Ohsawa, Gotaro Tanaka et al. · 2019 · Molecular Cancer Therapeutics
67. A case of resistance to tyrosine kinase inhibitor therapy
    Yanjun Xu, Zhiyu Huang, Lei Gong, Yun Fan · 2017 · Anti-Cancer Drugs
68. A momentous progress update: epidermal growth factor receptor inhibitors as viable agents for combating cancer
    Neha Jangra, Bharti Sharma, Deepak Kumar, Archana Kapoor · 2025 · RSC Medicinal Chemistry
69. Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
    Mazen Zaarour, Chanudi Kashmalee Weerasinghe, Bassel Nazha, Samer Hassan, Jean Paul Atallah · 2015 · Expert Review of Anticancer Therapy
70. Osimertinib for the treatment of non-small cell lung cancer
    Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2017 · Expert Opinion on Pharmacotherapy
71. Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort
    Houda Kaanane, Hicham El Attar, A. Louahabi, Hind Berradi, Hind Hassani Idrissi, Meriem Khyatti, Sellama Nadifi · 2019 · Gene
72. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations
    Xiaodan Yang, Jia Zhong, Zhuo Yu, Minglei Zhuo, Min Zhang, Rongrong Chen, Xuefeng Xia, Jun Zhao · 2021 · BMC Cancer
73. Bypassing checkpoints, overcoming resistance, and honing in on new targets
    Egbert Frederik Smit, Paul Baas · 2015 · Nature Reviews Clinical Oncology
74. Risk of Severe Rash in Cancer Patients Treated with Egfr Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis
    Xi Zhang, Yu-Ge Ran, Kunjie Wang · 2016 · Future Oncology
75. Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
    Long Mao, Wei Tang, Xiaoying Zhang, Jia Liu, Yile Chen, Yuning Hua, Bojie Weng, Xiaopeng Mo, Yimei Bao, Teng Li et al. · 2020 · Medicine in Drug Discovery
76. Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures
    Akito Hata, Nobuyuki Katakami, Shigeki Nanjo, Chiyuki Okuda, Reiko Kaji, Yukihiro Imai · 2017 · In Vivo
77. Is the Chemotherapy Era in Advanced Non-Small Cell Lung Cancer Really Over? Maybe not Yet
    Giuseppe Lo Russo, Martina Imbimbo, Marina Chiara Garassino · 2016 · Tumori Journal
78. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403
    Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, Kiichiro Ninomiya, Takashi Ninomiya, Toshio Kubo, Daisuke Minami, Toshi Murakami, Toshihide Yokoyama, Daijiro Harada et al. · 2016 · Clinical Lung Cancer
79. Treatment After First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in Non- Small-Cell Lung Cancer
    Seher Nazlı Kazaz, İlhan Öztop · 2017 · Turkish Thoracic Journal
80. Histological evolution from primary lung adenocarcinoma harboring EGFR mutation to high‐grade neuroendocrine carcinoma
    Jikai Zhao, Jinchen Shao, Ruiying Zhao, Rong Li, Keke Yu, Lei Zhu, Jie Zhang · 2017 · Thoracic Cancer
81. Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring
    Mostak Ahmed, Alain Wuethrich, Nicolas Constantin, Karthik Balaji Shanmugasundaram, Paul N. Mainwaring, Arutha Kulasinghe, Connor Gerard O’Leary, Kenneth John O'Byrne, Abu Ali Ibn Sina, Laura G. Carrascosa et al. · 2023 · Analytical Chemistry
82. A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases
    Catherine M. Boldig, Kimberly Boldig, Sepideh Mokhtari, Arnold B. Etame · 2024 · International Journal of Molecular Sciences
83. Epidermal Growth Factor Receptor Mutated Advanced Non–Small Cell Lung Cancer
    Suchita Pakkala, Suresh S. Ramalingam · 2016 · Hematology/Oncology Clinics of North America
84. A mechanistic study of thiol addition to N -phenylacrylamide
    Sarah K. I. Watt, Janique G. Charlebois, Christopher N. Rowley, Jeffrey W. Keillor · 2022 · Organic & Biomolecular Chemistry
85. Case report: Durable response to afatinib in a patient with lung cancer harboring two uncommon mutations of EGFR and a KRAS mutation
    Junko Tanizaki, Eri Banno, Yosuke Togashi, Hidetoshi Hayashi, Kazuko Sakai, Masayuki Takeda, Hiroyasu Kaneda, Kazuto Nishio, Kazuhiko Nakagawa · 2016 · Lung Cancer
86. HNSCC cells resistant to EGFR pathway inhibitors are hypermutated and sensitive to DNA damaging substances.
    Dominik Schulz, Markus Wirth, Guido Piontek, Anna Maria Stefanie Buchberger, Jürgen Schlegel, Rudolf Reiter, Gabriele Multhoff, Anja Pickhard · 2016 · PubMed Central
87. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance
    Shingo Nishikawa, Hideharu Kimura, Hayato Koba, Taro Yoneda, Satoshi Watanabe, Tamami Sakai, Johsuke Hara, Takashi Sone, Kazuo Kasahara, Shinji Nakao · 2018 · Journal of Thoracic Disease
88. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer
    Shoko Noda, Shintaro Kanda · 2016 · Expert Review of Respiratory Medicine
89. Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options
    Jordi Remón, Benjamin Besse · 2016 · ESMO Open
90. Synthesis of (-)-epigallocatechin-3-gallate derivative containing a triazole ring and combined with cisplatin/paclitaxel inhibits NSCLC cancer cells by decreasing phosphorylation of the EGFR
    Cheng‐Ting Zi, Peiyuan Sun, Ning Zhang, Han Tang, Hao-Nang Yang, Qi Wang, Yuna Wang, Jing Wang, Xuanjun Wang, Jun Sheng · 2020 · Journal of Chemical Research
91. Chromosomal Copy Number Variation Predicts EGFR-TKI Response and Prognosis for Patients with Non-Small Cell Lung Cancer
    Haiyan He, Hang Ma, Zhuo Chen, Jingliang Chen, Dandan Wu, Xuedong Lv, Jie Zhu · 2023 · Pharmacogenomics and Personalized Medicine
92. Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study
    Yosuke Wada, Shigeru Koyama, Hiroshi Kuraishi, Takashige Miyahara, Fumiaki Yoshiike, Toshihiko Agatsuma, Ryouhei Yamamoto, Yasushi Ono, Toshiro Suzuki, Tsutomu Hachiya et al. · 2016 · Respiratory Investigation
93. Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression
    Fedor Vladimirovich Moiseenko, Vladimir Mikhailovich Moiseyenko, Светлана Николаевна Алексахина, Vyacheslav A. Chubenko, Никита Михайлович Волков, Kseniya S. Kozyreva, Mikhail M Kramchaninov, Alexandr S. Zhuravlev, Ksenya V. Shelekhova, Alexandr O. Ivantsov et al. · 2016 · Oncology Research and Treatment
94. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations
    Toshihide Nishimura, Haruhiko Nakamura · 2016 · Advances in experimental medicine and biology
95. New systemic strategies for overcoming resistance to targeted therapies in non-small cell lung cancer
    Carlo Genova, Erika Rijavec, Federica Biello, Giovanni Rossi, Giulia Barletta, Maria Giovanna Dal Bello, Irene Vanni, Simona Coco, Angela Alama, Francesco Grossi · 2016 · Expert Opinion on Pharmacotherapy
96. PP03. HUMAN ENDOGENOUS RETROVIRUS TYPE K (HERVK) PROTEINS ARE OVEREXPRESSED AND RELEASED FROM HUMAN PRIMARY SCHWANNOMA CELLS CONTRIBUTING TO TUMOUR DEVELOPMENT VIA ERK, AKT, FAK PATHWAYS ACTIVATION AND P53 DOWNREGULATION
    Sylwia Ammoun, Mr Emmanuel Maze, Shona Reeves, David A. Hilton, Emanuela Ercolano, Prof Oliver Hamemann, Robert D. Belshaw · 2017 · Neuro-Oncology
97. An overall review of targeted therapy in solid cancers
    Vineet Talwar, Koyyala Venkata Pradeep Babu, Shubhra Raina · 2017 · Current Medicine Research and Practice
98. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer
    Bo Mi Ku, Jong‐Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2017 · Expert Review of Molecular Diagnostics
99. Phase Ib Study of High-dose Intermittent Afatinib in Patients With Advanced Solid Tumors
    D. Ross Camidge, Lecia Van Dam Sequist, Pasi Antero Janne, Andrew James Weickhardt, Elizabeth S. Dowling, Jeanette Alicea, Jean Fan, Geoffrey R. Oxnard · 2018 · Clinical Lung Cancer
100. AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
     Thomas E. Stinchcombe · 2016 · Europe PMC (PubMed Central)